Key result
Intramuscular injection of pMV64 DNA in mice induced N-specific IgG antibodies but provided no significant protective response against intracranial measles virus challenge.
Why the study?
Does intramuscular injection of pMV64 DNA induce protective immunity against measles virus challenge in mice?
Does intramuscular injection of pMV64 DNA induce protective immunity against measles virus challenge in mice?
DNA immunization with pMV64 induced antibodies but failed to protect mice against intracranial measles virus challenge, possibly due to slow and inefficient cell-mediated immune responses.
pMV64 DNA immunization elicits antibodies without protection in mice; leaves open whether optimized vectors or routes can achieve measles immunity.
The measles virus (MV) nucleocapsid (N) protein gene has been inserted into a plasmid vector so as to place the gene under the control of the strong constitutive human cytomegalovirus major immediate early promoter. On intramuscular injection of pMV64 DNA into C3H/He mice, seroconversion with increasing titers of N-specific serum IgG antibodies was observed over a period of 3 months. However, when 3-week-old mice were immunized by intramuscular injection of pMV64 in a two-dose schedule, and challenged intracranially with a rodent-adapted measles virus strain (CAM/RB) at 5 weeks of age, no significant protective response was seen. The lack of effective protection evoked by DNA immunization in this model, where MV challenge must take place before 8 weeks of age, may be due to inefficient induction of cell-mediated immunity resulting from expression in muscle tissue, compounded by a relatively slow rise in immune response compared with that seen with the recombinant adenovirus.
No takes yet. Share an insight, caveat, or question.
Fooks et al. (1996) studied Measles virus infection. pMV64 DNA was evaluated on Protective response against intracranial challenge with measles virus. Intramuscular injection of pMV64 DNA in mice induced N-specific IgG antibodies but provided no significant protective response against intracranial measles virus challenge.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: